Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Tennis star Serena Williams' candor about her GLP-1 use may help dispel the pesky health inaccuracy that weight loss is a ...

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Serena Williams has left fans concerned after she revealed a dramatic new-look following her major weight loss. The ...

The retired tennis pro explained that she’s trying to combat the stigma associated with weight loss drugs after losing 31 ...

Serena Williams, the tennis icon, has revealed her postpartum weight loss journey, shedding 31 pounds with the help of GLP-1 ...

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

Tennis legend Serena Williams reveals how she lost 14 kg by combining weight loss drugs with exercise and diet sharing a ...